Trial Profile
A study of non-responders for the treatment of age-related macular degeneration who switched therapy from bevacizumab to ranibizumab or vice versa
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Dec 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 18 Dec 2015 New trial record